Wockhardt sets timeline for resolving FDA bans; Sun profit suffers on Ranbaxy fold-in;

@FiercePharma: Tech makers market health wearables to dog owners. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Lundbeck's EU lobbying yields political boost for anti-alcohol med Selincro. Article | Follow @CarlyHFierce

> Wockhardt hopes to resolve the FDA ban on two of its plants by the end of its current fiscal year. More

> Sun Pharma's profits for the three months ended March 31 missed analysts estimates thanks to the cost of integrating new buy Ranbaxy Laboratories. Report

> A jury has ordered Abbott Laboratories ($ABT) to pay $23 million in punitive damages to a Minnesota girl whose family blamed the company's epilepsy drug Depakote for causing her birth defects. More

> The FDA has approved Pfizer's ($PFE) Rapamune to treat a rare lung disease. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Deerfield backs startup with $10M for its hemodialysis vascular access implant. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ info from the company: CareFusion's Avea ventilator recalled as potentially deadly. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific slapped with $100M verdict in vaginal mesh suit. News | Follow @EmilyWFierce

> Zimmer to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close. More

> Nonprofit leads $17.5M round for medical image exchange startup LifeImage. Article

Biotech News

@FierceBiotech: Buzz: Cellectis could be in a line for a $1.6B Pfizer buyout. Article | Follow @FierceBiotech

@JohnCFierce: Is this a good time to tout my survey (with Bloomberg Intelligence)? Are biotech assets overvalued? Check it out | Follow @JohnCFierce

> Merck hands its hep C combo to the FDA with sights on Gilead and AbbVie. More

> Heron soars as twice-rejected nausea drug comes through in Phase III. Report

And Finally... HIV treatment with antiretroviral drugs should begin immediately following diagnosis, U.S. health officials say. More (sub. req.)